Mark Iwicki - Pulmatrix Insider

Pulmatrix Inc -- USA Stock  

USD 1.26  0.02  1.61%

Chairman of the Board

Mr. Mark Iwicki is Independent Chairman of the Board of Pulmatrix, Inc. Mr. Iwicki has served as chairman of the Board and as a director of our Company since his appointment in December 2015. Mr. Iwicki currently serves as chairman of the board of directors and chief executive officer of Kala Pharmaceuticals. Prior to joining Kala, he was president and chief executive officer of Civitas Therapeutics, Inc., which was acquired by Acorda Therapeutics, Inc. in October 2014. Prior to joining Civitas, he served as president and chief executive officer at Blend Therapeutics, Inc., or Blend, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was president and chief executive officer of Sunovion Pharmaceuticals Inc., or Sunovion. Mr. Iwicki was at SepracorSunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was at Novartis Pharmaceuticals Corporationrationration from March 1998 to October 2007, where he was vice president and business unit head. Before that, he held management positions at Astra Merck Inc. and Merck Co., Inc. In addition to serving on our Board, Mr. Iwicki is currently a director at Kala Pharmaceuticals, Merus, Aimmune Therapeutics, Nimbus Therapeutics, Taris Biomedical and Oxeia Biopharmaceuticals. He previously served on the boards of Civitas, Sunovion and Blend, all privately held companies
Age: 49  Chairman Since 2015  MBA    
Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.

Management Efficiency

The company has return on total asset (ROA) of (48.95) % which means that it has lost $48.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (154.45) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.9 M in liabilities with Debt to Equity (D/E) ratio of 30.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.14 suggesting that it may have difficulties to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 24 people.Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 24 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Pulmatrix Inc to your portfolio

Top Management

Pulmatrix Inc Leadership Team
Terrance McGuire, Director, MBA
Matthew Sherman, Director
David Hava, Executive, Ph.D
Akihisa Akao, Director
James Roach, Executive, Ph.D
Michael Higgins, Director, MBA
Steven Gillis, Director
Jean Sung, President
William Duke, CFO, MBA
Robert Clarke, CEO, Ph.D
Scott Rocklage, Director, Ph.D
Kurt Graves, Director
Richard Conley, Director, MBA
Mark Iwicki, Chairman, MBA
Amit Munshi, Director, MBA
Gregory French, Director
David JD, Executive

Stock Performance

Pulmatrix Performance Indicators